Pharmaceutical Regulatory Intelligence: Tools, Strategies, and Impact on Product Lifecycle Management
Abstract
Regulatory Intelligence (RI) has become a critical strategic function in the pharmaceutical industry, enabling organizations to navigate complex and evolving global regulatory landscapes. By systematically collecting, analyzing, and disseminating regulatory information, RI supports proactive decision-making across the product lifecycle from early drug development to regulatory submissions and post-approval management. This review examines the tools, strategies, and impact of RI on Product Lifecycle Management (PLM). Traditional tools, such as regulatory authority databases, scientific literature, and internal knowledge repositories, provide foundational support, while digital and automated platforms including artificial intelligence (AI), machine learning, natural language processing, and Regulatory Information Management Systems (RIMS) enhance efficiency, predictive insights, and cross-functional collaboration. Effective RI strategies involve lifecycle-aligned planning, integration with clinical, quality, and commercial teams, performance monitoring, and proactive regulatory engagement. Case studies indicate that organizations with mature RI frameworks achieve faster approvals, optimized lifecycle management, and reduced compliance risks. Challenges include data overload, global regulatory variability, limitations of digital tools, and the absence of standardized performance metrics. Emerging trends, such as AI-enabled analytics, real-world evidence integration, blockchain, and advanced visualization, are expected to further strengthen RI’s strategic role. In conclusion, regulatory intelligence is a transformative tool that improves regulatory preparedness, supports strategic decision-making, and enhances the efficiency and sustainability of pharmaceutical product lifecycles.
Conclusion: Regulatory Intelligence (RI) plays a vital role in strengthening pharmaceutical Product Lifecycle Management by enabling proactive regulatory planning, improving compliance, and accelerating approvals. As digital technologies advance, RI will continue to enhance strategic decision-making and support sustainable innovation.
Downloads
References
doi:10.1208/s12248-024-01002-w
2. Beninger P. Signal management in pharmacovigilance: A review of activities and case studies. Clin Ther [Internet]. 2020 Jun [cited 2026 Feb 18];42(6):1110-29. Available from: doi:10.1016/j.clinthera.2020.03.018
3. Collier R, Singh A, Chopra S. Harnessing AI/ML in drug and biological products discovery and development: The regulatory perspective. Pharmaceuticals (Basel) [Internet]. 2025 Jan [cited 2026 Feb 18];18(1):47. Available from:
doi:10.3390/ph18010047
4. Dawar V, Sharma A, Mittal V, Sharma D. Global harmonization in drug approval: Bridging regulatory and clinical trial diversity. Curr Indian Sci [Internet]. 2024 [cited 2026 Feb 18];2(3). Available from:
https://currentindianscience.com
5. Di Bello F, Russo E, Sartori M. Enhancing regulatory affairs in medical device market placement using LLMs. AboutOpen [Internet]. 2024 [cited 2026 Feb 18];11(1):77-88. Available from: doi:10.33393/ao.2024.3302
6. Holm JEJ, Ruppert JG, Ramsden SD. Impact of changing regulations on European risk management plans. Pharm Med [Internet]. 2022 [cited 2026 Feb 18];36(1):33-46. Available from: doi:10.1007/s40290-021-00414-8
7. Liu Q, Huang R, Hsieh J, Zhu H, Tiwari M, Liu G, et al. Artificial intelligence and machine learning in regulatory submissions. Clin Pharmacol Ther [Internet]. 2023 Apr [cited 2026 Feb 18];113(4):771-4. Available from:
doi:10.1002/cpt.2668
8. Murali K, Kaur S, Prakash A, Medhi B. Artificial intelligence in pharmacovigilance: Practical utility. Indian J Pharmacol [Internet]. 2019 Nov-Dec [cited 2026 Feb 18];51(6):373-6. Available from:
doi:10.4103/ijp.IJP_814_19
9. Nimbalkar SS, Nagrale S. Pharmaceutical regulatory intelligence: Tools and lifecycle management impact. Int J Drug Regul Aff [Internet]. 2025 [cited 2026 Feb 18]. Available from: https://www.ijdra.com
10. Pantanowitz L, Hanna M, Pantanowitz J, Lennerz J, Henricks WH, Shen P, et al. Regulatory aspects of artificial intelligence and machine learning. Arch Pathol Lab Med [Internet]. 2024 Oct [cited 2026 Feb 18];148(10):1185-94. Available from:
doi:10.5858/arpa.2023-0123-RA
11. Santoro A, Genov G, Spooner A, Raine J, Arlett P. European Union pharmacovigilance system. Drug Saf [Internet]. 2017 Oct [cited 2026 Feb 18];40(10):855-69. Available from: doi:10.1007/s40264-017-0572-8
12. Silva MR, Santos LK, Oliveira PJ, et al. Artificial intelligence in Brazilian pharmaceutical regulation. Regul Sci Med Prod. 2024;14:189-98.
13. Sireesha B, Haritha S, Lakshmi Thriveni S, Nikitha P, Vijaya Lakshmi UVS. Regulatory requirements for new drug approval. Int J Health Care Biol Sci [Internet]. 2024 [cited 2026 Feb 18];5(4):22-8. Available from:
doi:10.46795/ijhcbs.v5i4.643
14. European Medicines Agency. HMA-EMA Joint Big Data Steering Group workplan 2022–2025 [Internet]. Amsterdam: EMA; 2023 [cited 2026 Feb 18]. Available from: https://www.ema.europa.eu
15. U.S. Food and Drug Administration. Artificial Intelligence and Machine Learning (AI/ML) Software as a Medical Device Action Plan [Internet]. Silver Spring (MD): FDA; 2021 [cited 2026 Feb 18]. Available from:
https://www.fda.gov
16. Leligkou HC, Gerogiannis VC. Deep transformers for predicting ALCOA+ data integrity compliance. Appl Sci [Internet]. 2023 [cited 2026 Feb 18];13(13):7616. Available from: doi:10.3390/app13137616
17. Rahman MS, Rahman MK, Kaykobad M, Rahman MS. Application of LIME and SHAP in Alzheimer’s disease detection. Brain Inform [Internet]. 2024 [cited 2026 Feb 18];11(1):4. Available from:
doi:10.1186/s40708-024-00213-9
18. Salunkhe P, Nagrale S. Electronic Common Technical Document (eCTD): Structure, Submission Process, and Regulatory Updates. Int J Drug Reg Affairs [Internet]. 2026 Mar.13[cited 2026Feb18];14(1):42-0.Available from: https://www.ijdra.com/index.php/journal/article/view/854
19. Yaeger KA, Martini M, Rasooly J, Samir AE, Louissaint A. Artificial intelligence-based image analysis in cytopathology. Cytopathology [Internet]. 2019 Oct [cited 2026 Feb 18];30(5):489-97. Available from:
doi:10.1111/cyt.12728
20. Bishnoi M, Sonker A. Emergency use authorization of medicines: History and ethical dilemma. Perspect Clin Res [Internet]. 2023 Apr-Jun [cited 2026 Feb 18];14(2):49-55. Available from: doi:10.4103/picr.picr_149_22
21. Craveiro NS, Lopes BS, Tomás L, Almeida SF. Drug withdrawal due to safety: A review of the data supporting withdrawal decision. Curr Drug Saf [Internet]. 2020 [cited 2026 Feb 18];15(1):4-12. Available from:
doi:10.2174/1574886314666191004092520
22. Dirks A, Florez M, Torche F, Young S, Slizgi B, Getz K. Comprehensive assessment of risk-based quality management adoption in clinical trials. Ther Innov Regul Sci [Internet]. 2024 [cited 2026 Feb 18];58:520-7. Available from: doi:10.1007/s43441-024-00618-5
23. Gozzo L. Pharmacovigilance and appropriate drug use. Healthcare (Basel) [Internet]. 2024 Jun [cited 2026 Feb 18];12(6):669. Available from:
doi:10.3390/healthcare12060669
24. Harmark L, van Grootheest AC. Pharmacovigilance: Methods, recent developments and future perspectives. Eur J Clin Pharmacol [Internet]. 2008 Aug [cited 2026 Feb 18];64(8):743-52. Available from:
doi:10.1007/s00228-008-0475-9
25. ICH Q8–Q10 Pharmaceutical Development, Quality Risk Management and Pharmaceutical Quality System guidelines [Internet]. Geneva: ICH; 2009 [cited 2026 Feb 18]. Available from: https://www.ich.org
26. Jeetu G, Anusha G. Pharmacovigilance: A worldwide master key for drug safety monitoring. J Young Pharm [Internet]. 2010 Jul-Sep [cited 2026 Feb 18];2(3):315-20. Available from: doi:10.4103/0975-1483.66802
27. Kandukuri A, Edla DR. Ensuring data safety in pharmacovigilance: Processes and regulatory perspectives. Asian J Pharm Res Dev [Internet]. 2025 [cited 2026 Feb 18];13(3):1569. Available from:
doi:10.22270/ajprd.v13i3.1569
28. Lucas S, Ailani J, Smith TR, Abdrabboh A, Xue F, Navetta MS. Pharmacovigilance reporting requirements throughout a product lifecycle. Ther Adv Drug Saf [Internet]. 2022 [cited 2026 Feb 18];13. Available from:
doi:10.1177/20420986221125006
29. Robinson F, Wilkes S, Schaefer N, Goldstein M, Rice M, Gray J, et al. Patient-centered pharmacovigilance: Priority actions from inherited bleeding disorders community. Ther Adv Drug Saf [Internet]. 2023 [cited 2026 Feb 18];14. Available from: doi:10.1177/20420986221146418
30. Sardella M, Belcher G, Lungu C, Ignoni T, Camisa M, Stenver DI, et al. Monitoring manufacturing quality of medicines: A fundamental task of pharmacovigilance. Ther Adv Drug Saf [Internet]. 2021 [cited 2026 Feb 18];12. Available from: doi:10.1177/20420986211038436
31. Talbot JC, Nilsson BS. Pharmacovigilance in the pharmaceutical industry. Br J Clin Pharmacol [Internet]. 1998 May [cited 2026 Feb 18];45(5):427-31. Available from: doi:10.1046/j.1365-2125.1998.00713.x
32. Trippe ZA, Brendani B, Meier C, Lewis D. Identification of substandard medicines via disproportionality analysis of individual case safety reports. Drug Saf [Internet]. 2017 Apr [cited 2026 Feb 18];40(4):293-303. Available from:
doi:10.1007/s40264-016-0499-5
33. CDSCO alerts: Retrospective dosage form-wise analysis of quality control alerts issued to pharmaceutical companies from 2018 to 2023. Regul Toxicol Pharmacol [Internet]. 2025 [cited 2026 Feb 18];156:105775. Available from:
doi:10.1016/j.yrtph.2025.105775
34. Alemayehu C, Mitchell G, Nikles J. Barriers for conducting clinical trials in developing countries: A systematic review. Int J Equity Health [Internet]. 2018 [cited 2026 Feb 18];17:37. Available from:
doi:10.1186/s12939-018-0748-6
35. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Common Technical Document for the registration of pharmaceuticals for human use (M4) [Internet]. Geneva: ICH; 2020 [cited 2026 Feb 18]. Available from:
https://www.ich.org
36. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH E6(R3) Good Clinical Practice guideline [Internet]. Geneva: ICH; 2025 [cited 2026 Feb 18]. Available from:
https://www.ich.org
37. Khan MAA, Hamid S, Khan SA, Sarfraz M, Babar ZUD. Stakeholders’ views on pharmacovigilance system and policy coordination in Pakistan. Front Pharmacol [Internet]. 2022 [cited 2026 Feb 18];13:891954. Available from: doi:10.3389/fphar.2022.891954
38. Niazi SK, Al-Shaqha WM, Mirza Z. Proposal of International Council for Harmonization guideline for approval of biosimilars. J Mark Access Health Policy [Internet]. 2022 [cited 2026 Feb 18];11(1). Available from:
doi:10.1080/20016689.2022.2147286
39. Rewale KS, Tuwar AB, Salve MT. Brief review on pharmacovigilance. Int J Pharm Sci Drug Anal [Internet]. 2024 [cited 2026 Feb 18];4(1):9-16.
40. Suresh V, Kumar KS. Approval and marketing of medical products in EU, USA, India and Australia. Asian J Med Pharm Sci [Internet]. 2023 [cited 2026 Feb 18];11(1):73-82. Available from: doi:10.30904/j.ajmps.2023.4619
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM
